文献
501. Bissonnette B, Dalens B. Pediatric anesthesia Principles & Method. McGraw-Hill 2002: 259-265.
502. Clotz MA, Nahata MC. Clinical use of fentanyl, sufentanyl and alfentayl. Clin Phar 1991; 10: 581-593.
503. Hickley PR, Hansen DD, Wessel Dl. Pulmoary and systemic hemodynamic response to fentanyl in infants. Anesth Analg 1985; 65: 483-486.
504. Pasternak GW, Bondnar RJ, Clerk JA, et al. morphine-6-glucronide, a potent mu agonist. Life Sci 1987; 41: 2845-2849.
505. Radnay PA, Duncalf D, Novakovic M, et al. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol and naloxone.
Anesth Analg 1984; 63: 441-444.
506. Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85: 721-728.
507. Reid JE, Mirakhur RK. Bradycardia after administration of remifentanil. Br J Anaesth 2000; 84: 422-423.
508. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver
disease.Anesthesiology 1996; 84: 812-820.
509. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with
healthy volunteers. Anesthesiology 1997; 87: 533-541.
510. Ross AK, Davis PJ, Dear Gd GL, et al. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic
procedures. Anesth Analg 2001; 93: 1393-1401( Ⅱ-c).
511. Chung F, Mulier JP, Scholz J, et al. A comparison of anaesthesia using remifentanyl combined with either Isoflurane, Enflurane or propofol in patients
underging gynaecological laparoscopy, varicose vein or arthroscopic surgery. Acta Anaesthesiol Scand 2000; 44: 790-798.
512. Wilhelm W, Grundmann U, Van Aken H, et al. A multicenter comparison of isoflurane and propofol as adjuncts to remifentanyl-based anesthesia.
J Clin Anesth 2000; 12:129-135.
513. Doufas AG, Lin CM, Suleman MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshole in humans. Stroke 2003; 34:
1218-1223.
514. Kose EA, Dal D, Kinci SB, et al. The efficacy of ketamine for the treatment of postoperative shivering. Anesth Analg 2008; 106: 120-122.
515. Albrecht S, Schuttler J, Yarmush J. Postoperative pain management after intraoperative remifentanyl. Anesth Analg 1999; 89: S40-S45.
516. Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-573.
517. Lin C, Durieux ME. Ketamine and kids: an update. Pesiatr Anesth 2005; 15: 91-97.
518. Takeshita H, Okuda Y, et al. The effects of ketamine on cerebral circulation and metabolism in man.Anesthesiology 1972; 36: 69-75.
519. Harrison NL, Sear JW. Chapter 24- Intravenous anesthetics: barbiturates, etomidate, propofol, ketamne, and steroids. In Evers AS, Maze M (eds).
Anesthetic pharmacology. Churchill Livingstone 2004: 395-416.
520. Roberts IG. Barbiturates for acute traumatic brain injury. Cochrane Database of Syst Rev 1999; 3: CD000033.
521. Jhonson TN, Rostami-Hodjegan A, Goddard JM, et al. Contribution of midazolam and its 1-hydroxy metabolic to preoperative sedation in children:
a pharmacokineticpharmacodynamic analysis. Br J Anaesth 2002; 89: 428-437.
522. Servin F, Cockshott ID, Farintti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990; 65: 177-183.
523. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease.
Br J Anaesth 1998; 81: 854-860.
524. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndorome. Intensive Cara
Med 2003; 29: 1417-1425.
525. Wolf A, Wier P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357: 606-607.
526. Playfor S, Jenkins I, Boyles C, et al., United Kingdom Paediatric Intensive Care Society Sedation; Analgesia and Neuromuscular Blockade Working
Group. Consensus guidelines on sedation and analgesia in critically ill children. Intensive Care Med 2006; 32: 1125-1136.
527. Koroglu A, Tekasan H, Sagir O, et al. A comparison of the sedative, hemodynamic, and respiratory effect of dexmedetomidine and propofol in children
undergoing resonance imaging. Anesth Analg 2006; 103: 63-67.
528. Berkenbosch JW, Wankun PC, Tobias JD, et al. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Peidatr
Crit Care Med 2005; 6: 435-439.
529. Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Pediatr Drugs 2008; 10: 49-69.
530. Petroz GC, Sikich N, James M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children.
Anesthesiology 2006; 105: 1098-1110 (II-c).
531. 新宮 興，増澤宗洋，表圭一，他．Org9426（臭化ロクロニウム）の筋弛緩作用-臭化ベクロニウムとの比較-.麻酔 2006; 55; 1140-1148（I）.
532. Khuenl-Brady K, Castagnoli KP, Canfell PC, et al. The neuromuscular blocking effect and pharmacokinetics of ORG9426 and ORG 9616 in the cat.
Anesthesiology 1990; 72: 669-674.
533. Wierda JM, Kleef UW, Lambalk LM, et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking
agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anesth 1991; 38: 430-435.
534. Shevchenko Y, Jocson JC, McRae VA, et al. The use of lidcaine for preventing the withdrawal associated with the injection of rocuronium in children
and adolescents. Anesth Analg 1999; 88: 746-748.
535. Niwa K, Nakazawa M, Miyatake K, et al. Survey of prophylaxis and management of infective endocarditis in patients with congenital heart disease
-Japanese nationwide survey-. Circ J 2003; 67: 585-591.
536. Ferrieri P, Gewitz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Circulation 2002; 105: 2115-2126.
537. Day MD, Gauvreau K, Shulman S, et al. Characteristics of children hospitalized with infective endocarditis. Circulation 2009; 119: 865-870.
538. 循環器病の診断と治療に関するガイドライン．感染性心内膜炎の予防 と治療に関するガイドライン（2008年改訂版）.
http://www.j-circ.or.jp/guideline/pdf/JCS2008_miyatake_h.pdf
539. Filippo SD, Delahaya F, Semiond B, et al. Current patterns of infective endocarditis in congenital heart disease. Heart 2006; 92: 1490-1495.
540. 中澤誠，石和田稔彦，市田蕗子，他．小児心疾患と成人先天性心疾患における感染性心内膜炎の管理，治療と予防ガイドライン．日小循誌 2011（掲載待ち）．
541. Niwa K, Nakazawa M, Tateno S, et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart 2005; 91:
795-800.
542. Yoshinaga M, Niwa K, Niwa A, et al. Risk factors for inhospital mortality during infective endocarditis in patients with congenital heart disease.
Am J Cardiol 2008; 101: 114-118.
543. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002; 49: 437-444.
544. Ishiwada N, Niwa K, Tateno S, et al. Pneumococcal endocarditis in children: A nationwide survey in Japan. Int J Cardiol 2007; 123: 298-301.
545. Huang JH, Hsu RB. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: Teicoplanin versus Vancomycin
in a retrospective study. Scand J Infect Dis 2008; 40: 462-467.
546. Hasegawa K, Yamamoto K, Chiba N, et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb
Drug Resist 2003; 9: 39-46.
547. Osmon S, Ward S, Fraser VJ, et al. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.
Chest 2004; 125: 607-616.
548. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
549. Ishiwada N, Niwa K, Tateno S, et al. Causative organisms influences clinical profile and outcome of infective endocarditis in pediatric patients and
adults with congenital heart disease. Circ J 2005; 69: 1266-1270.
550. Nakatani S, Mitsutake K, Hozumi T, et al. Current characteristics of infective endocarditis in Japan: an analysis of 848 cases in 2000 and 2001.
Circ J 2003; 67: 901-905.
551. Onoda K, Mizutani H, Komada T, et al. Atopic dermatitis as a risk factor for acute native valve endocarditis. J Heart Valve Dis 2000; 9: 469-471.
552. Zamorano J, Sanz J, Almeria C, et al. Differences between endocarditis with true negative blood cultures and those with previous antibiotic treatment.
J Heart Valve Dis 2003; 12: 256-260.
553. Breitkopf C, Hammel D, Schld HH, et al. Impact of a molecular approach to improve the maicrobiological diagnosis of infective heart valve endocarditis.
Circulation 2005; 111: 1415-1421.
554. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis.Guidelines from the American Heart Association. Circulation 2007; 116:
1736-1754.
555. Lockhart PB, Brennan MT, Kent ML, et al. Impact of amoxicillin prophylaxis on the incidence, nature, and duration of bacteremia in children after
intubation and dental procedures. Circulation 2004; 109: 2878-2884.
556. Nishi J, Yoshinaga M, Nomura Y, et al. Prevalence of Penicillin-resistant viridans Streptococci in the oral flora of Japanese children at risk for infective
endocarditis. Circulation 1999; 99: 1274-1275.
557. 石和田稔彦. わが国における小児および成人先天性心疾患における感染性心内膜炎の実態. 小児感染免疫 2005; 17: 315-324.
558. 循環器病の診断と治療に関するガイドライン. 成人先天性心疾患診療ガイドライン（2011年改訂版）. http://www. j-circ.or.jp/guideline/pdf/JCS2011_niwa_h.pdf
559. Moore KI, Persaud TVN. Before we are born: Essential of Embryology and birth defects, 6th edn. Philadelphia, PA: W. B. Saunders 2003: 263-304.
560. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Cochrane Datebese of Systematic Reviews, Issure2, Art.no.CD003480,DOI:10.1002/14651858. CD003480.pub3:2007
561. Yeh TF, et al. Intravenous indomethacin therapy in premature infants with persistant ductus arteriosus- a double blind controlled study. J Pediatr
1981; 98: 137.
562. Archer N. Cardiovascular disease Roberton’s Textbook of neonatology,4th edn. Philadelphia, PA, Elsevier Churchill Livingston 2005: 619-660.
563. 豊島勝昭，森臨太郎，西原正泰，他．医療の標準化PDAの診断と治療．未熟児新生児誌 21; 2009: 191-198.
564. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in
preterm infants. Cochrane Database Syst Rev 2008; 1: CD003951. Review.
565. Gork AS, Ehrenkranz RA, Bracken MB. Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure
in symptomatic preterm infants. Cochrane Database Syst Rev 2008; 1: CD006071.
566. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst
Rev 2002; 3: CD000174.
567. 諫山哲哉，平野慎也，森臨太郎，他．早産児における予防的経静脈的インドメタシン投与の有効性の検討 2002 年Cochrane ReviewとNeonatal Research
Network（NRN）研究とのメタアナリシス. 未熟児新生児誌 2008; 20: 479.
568. Vohr BR, Allan WC, Ment LR, et al. School-age outcomes of very low birth wight infants in the indomethacin intraventricular hemorrage prevention
trial. Pediatrics 2003; 111: e340-346.
569. Shinya Hirano, Masanori Fujimura, Satoshi Kusuda. Prevalence of cerebral palsy at 3-5 years of age who participated in an RCT for the prevention of
intraventricular hemorrhage by indomethacin in Japanese extremely low birthweight infants. On behalf of the Neonatal Research Network Japan
Pediatric Academic Societies and Asian Society for Pediatric Research 2008 Joint Meeting.
570. Schmidt,B, et al. Long-term effects of Indomethacin prophylaxis in extremely-low-birth weight infants. N Engl J Med 2001; 344: 1966-1972.
571. 長屋建，青柳裕之，森臨太郎，他．未熟児動脈管開存症の外科的治療において手術例数が多い施設での治療は手術例数が少ない施設の治療に比べて合
併症は少ないか（効果的か）?未熟児動脈管開存症診療ガイドラインから（第二報）．未熟児新生児誌 2008; 20: 479.
572. Overmeire BV, et al. A comparison of ibuprofen and indomethacin for patent ductus arteriosus. N Engl J Med 2000; 343: 674-681.
573. Thomas RL, et al. A meta-analysis of ibuprofen versus indomethacin for closere of patient ductus arteriosus. Eur J Pediar 2005; 164: 135-140.
574. OhlssonA, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of
Systematic Review, Issue1, art, No.CD003481.DOI:10.1002/14651858.CD003481.pub3.
575. Seri I. Management of hypotention and low systemic blood flow in the very low birth weight neonates during the first postnatal week. J Perinatol 2006;
26: S8-S13.
576. Tsuji M, Saul JP, du Plessis A, et al. Cerebral intravascular oxygenation correlates with mean arterial pressure in critically ill premature infants.
Padiatr 2000; 106: 625-632.
577. Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants, Cochrane Datebase of Systematic Reviews 2003, issure 3.
[DOI:10.1002/14651858. CD001242]
578. Levene MI, Tudehope DI, Sinha S. Essential neonatal medicine, 4th edn. Oxford, Blackwell 2008: 176-192.
579. Osborn DA, Evans N, Kluckow M. Clinical detection of low upper body blood flow in very preterm infants using blood pressure ,critical refill time, and
central-peripheral temperature difference. Arch Dis Childh: Fetal and Neonatal Edition 2004; 89: F168-173.
580. Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow,Arch Dis Childh:Fetal and Neonatal Edition
2000; 82: F182-187.
581. Kourembanas S. ’Shock’ Manual of neonatal care, 6th edn. Philadelphia, PA: Lippincott 2008: 176-180.
582. So KW, Fol TF, Cheung KL, et al. Randomised control trial of colloid or crystalloid in hypotensive preterm infants.1997; 76: F43-46.
583. Osborn DA, Evans N, Kluckow M. Randomised trial of dobutamine versus dopamine in preterm infants with low systemic blood flow J Pediatr 2002 ;
140: 183-190.
584. Osborn DA, Paradisis M, Evans N. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow.
Cochrane Datebase of Systematic Reviews 2007; Issue 1.[DOI:10.1002/14651858. CD005090]
585. Berrington KJ, Finer NN, Chan WKY. A blind randomized comparison of the circulatory effects of dopamine and epinrphline infusion in the newborn
piglet during normoxia and hypoxia.Critical Care Medicine 1995; 23: 740-748.
586. Paradisis M, Osborn DA. Adrenalin for prevention of morvidity and mortality in preterm infants with cardiovascular compromise. Cochrane Datebase of
Systematic Reviews 2004; Issue 1.[DOI:10.1002/14651858.CD003958]
587. 2005 International Liaison Committee on Resuscitation, American Heart Association, and European Resuscitation Counci. 2005 American Heart
Association Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Part7. Neonatal Resuscitaion. Circulation 2005;
112(suppl): Ⅲ 91-99.
588. 日本版救急蘇生ガイドライン2010に基づく新生児蘇生法テキスト 改訂第2版．東京，メディカルビュー社 2010: 76-83.
589. Ng PC, Lam CW, Fok TF, et al. Refractory hypotention in preterm infants with adrenocorticol insufficiency.Arch Dis Childlh: Fetal and Neonatal Edn
2001; 84: F122-124.
590. Seri I. Hydrocortisone and vasopuressor-resistant shock in preterm neonates Pediatr 2006; 117: 516-518.
591. Ng PC, Cheuk LH, Bnur FL, et al . A double blind,randomized,controlled study of a stress dose of hydrocortisone for rescue treatment of refractory
hypotention in preterm infants. Pediatr 2006; 117: 367-375.
592. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91:
283-290.
593. Van Marter LJ. Persistent pulmonary hypertension of the newborn. Manual of neonatal care 6th edn. Philadelphia, PA: Lippincott 2008: 358-364.
594. Kinsella JP, Abman SH. Clinical approach to inhaled NO therapy in the newborn. J pediatrics 2000; 136: 717-726.
595. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistant pulmonary hypertention of the newborn. N Engl J Med 2000;
342: 469-474.
596. Finer N, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term(Review). Cochrane Database Syst Rev 2006; 4: CD000399.
597. Rang HP, Dale MM, Ritter JM, et al. Rang and Dole’spharmacology, 6th edn. Philadelphia, PA: Churchill Livingstone Elsevier 2007: 331-346.
598. 佐地勉，山田修，中山智孝，他．小児期肺動脈性肺高血圧症症例におけるエポプロステノール治療の有効性と安全性の長期検討―市販後使用成績調査から
の検討―．心臓2008; 40: 34-43.
599. Bronen M. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997; 18: 3-7.
600. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study.
Pediatrics 2006; 117: 1077-1083.
502. Clotz MA, Nahata MC. Clinical use of fentanyl, sufentanyl and alfentayl. Clin Phar 1991; 10: 581-593.
503. Hickley PR, Hansen DD, Wessel Dl. Pulmoary and systemic hemodynamic response to fentanyl in infants. Anesth Analg 1985; 65: 483-486.
504. Pasternak GW, Bondnar RJ, Clerk JA, et al. morphine-6-glucronide, a potent mu agonist. Life Sci 1987; 41: 2845-2849.
505. Radnay PA, Duncalf D, Novakovic M, et al. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol and naloxone.
Anesth Analg 1984; 63: 441-444.
506. Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85: 721-728.
507. Reid JE, Mirakhur RK. Bradycardia after administration of remifentanil. Br J Anaesth 2000; 84: 422-423.
508. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver
disease.Anesthesiology 1996; 84: 812-820.
509. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with
healthy volunteers. Anesthesiology 1997; 87: 533-541.
510. Ross AK, Davis PJ, Dear Gd GL, et al. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic
procedures. Anesth Analg 2001; 93: 1393-1401( Ⅱ-c).
511. Chung F, Mulier JP, Scholz J, et al. A comparison of anaesthesia using remifentanyl combined with either Isoflurane, Enflurane or propofol in patients
underging gynaecological laparoscopy, varicose vein or arthroscopic surgery. Acta Anaesthesiol Scand 2000; 44: 790-798.
512. Wilhelm W, Grundmann U, Van Aken H, et al. A multicenter comparison of isoflurane and propofol as adjuncts to remifentanyl-based anesthesia.
J Clin Anesth 2000; 12:129-135.
513. Doufas AG, Lin CM, Suleman MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshole in humans. Stroke 2003; 34:
1218-1223.
514. Kose EA, Dal D, Kinci SB, et al. The efficacy of ketamine for the treatment of postoperative shivering. Anesth Analg 2008; 106: 120-122.
515. Albrecht S, Schuttler J, Yarmush J. Postoperative pain management after intraoperative remifentanyl. Anesth Analg 1999; 89: S40-S45.
516. Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-573.
517. Lin C, Durieux ME. Ketamine and kids: an update. Pesiatr Anesth 2005; 15: 91-97.
518. Takeshita H, Okuda Y, et al. The effects of ketamine on cerebral circulation and metabolism in man.Anesthesiology 1972; 36: 69-75.
519. Harrison NL, Sear JW. Chapter 24- Intravenous anesthetics: barbiturates, etomidate, propofol, ketamne, and steroids. In Evers AS, Maze M (eds).
Anesthetic pharmacology. Churchill Livingstone 2004: 395-416.
520. Roberts IG. Barbiturates for acute traumatic brain injury. Cochrane Database of Syst Rev 1999; 3: CD000033.
521. Jhonson TN, Rostami-Hodjegan A, Goddard JM, et al. Contribution of midazolam and its 1-hydroxy metabolic to preoperative sedation in children:
a pharmacokineticpharmacodynamic analysis. Br J Anaesth 2002; 89: 428-437.
522. Servin F, Cockshott ID, Farintti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990; 65: 177-183.
523. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease.
Br J Anaesth 1998; 81: 854-860.
524. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndorome. Intensive Cara
Med 2003; 29: 1417-1425.
525. Wolf A, Wier P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357: 606-607.
526. Playfor S, Jenkins I, Boyles C, et al., United Kingdom Paediatric Intensive Care Society Sedation; Analgesia and Neuromuscular Blockade Working
Group. Consensus guidelines on sedation and analgesia in critically ill children. Intensive Care Med 2006; 32: 1125-1136.
527. Koroglu A, Tekasan H, Sagir O, et al. A comparison of the sedative, hemodynamic, and respiratory effect of dexmedetomidine and propofol in children
undergoing resonance imaging. Anesth Analg 2006; 103: 63-67.
528. Berkenbosch JW, Wankun PC, Tobias JD, et al. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Peidatr
Crit Care Med 2005; 6: 435-439.
529. Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Pediatr Drugs 2008; 10: 49-69.
530. Petroz GC, Sikich N, James M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children.
Anesthesiology 2006; 105: 1098-1110 (II-c).
531. 新宮 興，増澤宗洋，表圭一，他．Org9426（臭化ロクロニウム）の筋弛緩作用-臭化ベクロニウムとの比較-.麻酔 2006; 55; 1140-1148（I）.
532. Khuenl-Brady K, Castagnoli KP, Canfell PC, et al. The neuromuscular blocking effect and pharmacokinetics of ORG9426 and ORG 9616 in the cat.
Anesthesiology 1990; 72: 669-674.
533. Wierda JM, Kleef UW, Lambalk LM, et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking
agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anesth 1991; 38: 430-435.
534. Shevchenko Y, Jocson JC, McRae VA, et al. The use of lidcaine for preventing the withdrawal associated with the injection of rocuronium in children
and adolescents. Anesth Analg 1999; 88: 746-748.
535. Niwa K, Nakazawa M, Miyatake K, et al. Survey of prophylaxis and management of infective endocarditis in patients with congenital heart disease
-Japanese nationwide survey-. Circ J 2003; 67: 585-591.
536. Ferrieri P, Gewitz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Circulation 2002; 105: 2115-2126.
537. Day MD, Gauvreau K, Shulman S, et al. Characteristics of children hospitalized with infective endocarditis. Circulation 2009; 119: 865-870.
538. 循環器病の診断と治療に関するガイドライン．感染性心内膜炎の予防 と治療に関するガイドライン（2008年改訂版）.
http://www.j-circ.or.jp/guideline/pdf/JCS2008_miyatake_h.pdf
539. Filippo SD, Delahaya F, Semiond B, et al. Current patterns of infective endocarditis in congenital heart disease. Heart 2006; 92: 1490-1495.
540. 中澤誠，石和田稔彦，市田蕗子，他．小児心疾患と成人先天性心疾患における感染性心内膜炎の管理，治療と予防ガイドライン．日小循誌 2011（掲載待ち）．
541. Niwa K, Nakazawa M, Tateno S, et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart 2005; 91:
795-800.
542. Yoshinaga M, Niwa K, Niwa A, et al. Risk factors for inhospital mortality during infective endocarditis in patients with congenital heart disease.
Am J Cardiol 2008; 101: 114-118.
543. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002; 49: 437-444.
544. Ishiwada N, Niwa K, Tateno S, et al. Pneumococcal endocarditis in children: A nationwide survey in Japan. Int J Cardiol 2007; 123: 298-301.
545. Huang JH, Hsu RB. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: Teicoplanin versus Vancomycin
in a retrospective study. Scand J Infect Dis 2008; 40: 462-467.
546. Hasegawa K, Yamamoto K, Chiba N, et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb
Drug Resist 2003; 9: 39-46.
547. Osmon S, Ward S, Fraser VJ, et al. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.
Chest 2004; 125: 607-616.
548. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
549. Ishiwada N, Niwa K, Tateno S, et al. Causative organisms influences clinical profile and outcome of infective endocarditis in pediatric patients and
adults with congenital heart disease. Circ J 2005; 69: 1266-1270.
550. Nakatani S, Mitsutake K, Hozumi T, et al. Current characteristics of infective endocarditis in Japan: an analysis of 848 cases in 2000 and 2001.
Circ J 2003; 67: 901-905.
551. Onoda K, Mizutani H, Komada T, et al. Atopic dermatitis as a risk factor for acute native valve endocarditis. J Heart Valve Dis 2000; 9: 469-471.
552. Zamorano J, Sanz J, Almeria C, et al. Differences between endocarditis with true negative blood cultures and those with previous antibiotic treatment.
J Heart Valve Dis 2003; 12: 256-260.
553. Breitkopf C, Hammel D, Schld HH, et al. Impact of a molecular approach to improve the maicrobiological diagnosis of infective heart valve endocarditis.
Circulation 2005; 111: 1415-1421.
554. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis.Guidelines from the American Heart Association. Circulation 2007; 116:
1736-1754.
555. Lockhart PB, Brennan MT, Kent ML, et al. Impact of amoxicillin prophylaxis on the incidence, nature, and duration of bacteremia in children after
intubation and dental procedures. Circulation 2004; 109: 2878-2884.
556. Nishi J, Yoshinaga M, Nomura Y, et al. Prevalence of Penicillin-resistant viridans Streptococci in the oral flora of Japanese children at risk for infective
endocarditis. Circulation 1999; 99: 1274-1275.
557. 石和田稔彦. わが国における小児および成人先天性心疾患における感染性心内膜炎の実態. 小児感染免疫 2005; 17: 315-324.
558. 循環器病の診断と治療に関するガイドライン. 成人先天性心疾患診療ガイドライン（2011年改訂版）. http://www. j-circ.or.jp/guideline/pdf/JCS2011_niwa_h.pdf
559. Moore KI, Persaud TVN. Before we are born: Essential of Embryology and birth defects, 6th edn. Philadelphia, PA: W. B. Saunders 2003: 263-304.
560. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Cochrane Datebese of Systematic Reviews, Issure2, Art.no.CD003480,DOI:10.1002/14651858. CD003480.pub3:2007
561. Yeh TF, et al. Intravenous indomethacin therapy in premature infants with persistant ductus arteriosus- a double blind controlled study. J Pediatr
1981; 98: 137.
562. Archer N. Cardiovascular disease Roberton’s Textbook of neonatology,4th edn. Philadelphia, PA, Elsevier Churchill Livingston 2005: 619-660.
563. 豊島勝昭，森臨太郎，西原正泰，他．医療の標準化PDAの診断と治療．未熟児新生児誌 21; 2009: 191-198.
564. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in
preterm infants. Cochrane Database Syst Rev 2008; 1: CD003951. Review.
565. Gork AS, Ehrenkranz RA, Bracken MB. Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure
in symptomatic preterm infants. Cochrane Database Syst Rev 2008; 1: CD006071.
566. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst
Rev 2002; 3: CD000174.
567. 諫山哲哉，平野慎也，森臨太郎，他．早産児における予防的経静脈的インドメタシン投与の有効性の検討 2002 年Cochrane ReviewとNeonatal Research
Network（NRN）研究とのメタアナリシス. 未熟児新生児誌 2008; 20: 479.
568. Vohr BR, Allan WC, Ment LR, et al. School-age outcomes of very low birth wight infants in the indomethacin intraventricular hemorrage prevention
trial. Pediatrics 2003; 111: e340-346.
569. Shinya Hirano, Masanori Fujimura, Satoshi Kusuda. Prevalence of cerebral palsy at 3-5 years of age who participated in an RCT for the prevention of
intraventricular hemorrhage by indomethacin in Japanese extremely low birthweight infants. On behalf of the Neonatal Research Network Japan
Pediatric Academic Societies and Asian Society for Pediatric Research 2008 Joint Meeting.
570. Schmidt,B, et al. Long-term effects of Indomethacin prophylaxis in extremely-low-birth weight infants. N Engl J Med 2001; 344: 1966-1972.
571. 長屋建，青柳裕之，森臨太郎，他．未熟児動脈管開存症の外科的治療において手術例数が多い施設での治療は手術例数が少ない施設の治療に比べて合
併症は少ないか（効果的か）?未熟児動脈管開存症診療ガイドラインから（第二報）．未熟児新生児誌 2008; 20: 479.
572. Overmeire BV, et al. A comparison of ibuprofen and indomethacin for patent ductus arteriosus. N Engl J Med 2000; 343: 674-681.
573. Thomas RL, et al. A meta-analysis of ibuprofen versus indomethacin for closere of patient ductus arteriosus. Eur J Pediar 2005; 164: 135-140.
574. OhlssonA, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of
Systematic Review, Issue1, art, No.CD003481.DOI:10.1002/14651858.CD003481.pub3.
575. Seri I. Management of hypotention and low systemic blood flow in the very low birth weight neonates during the first postnatal week. J Perinatol 2006;
26: S8-S13.
576. Tsuji M, Saul JP, du Plessis A, et al. Cerebral intravascular oxygenation correlates with mean arterial pressure in critically ill premature infants.
Padiatr 2000; 106: 625-632.
577. Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants, Cochrane Datebase of Systematic Reviews 2003, issure 3.
[DOI:10.1002/14651858. CD001242]
578. Levene MI, Tudehope DI, Sinha S. Essential neonatal medicine, 4th edn. Oxford, Blackwell 2008: 176-192.
579. Osborn DA, Evans N, Kluckow M. Clinical detection of low upper body blood flow in very preterm infants using blood pressure ,critical refill time, and
central-peripheral temperature difference. Arch Dis Childh: Fetal and Neonatal Edition 2004; 89: F168-173.
580. Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of systemic blood flow,Arch Dis Childh:Fetal and Neonatal Edition
2000; 82: F182-187.
581. Kourembanas S. ’Shock’ Manual of neonatal care, 6th edn. Philadelphia, PA: Lippincott 2008: 176-180.
582. So KW, Fol TF, Cheung KL, et al. Randomised control trial of colloid or crystalloid in hypotensive preterm infants.1997; 76: F43-46.
583. Osborn DA, Evans N, Kluckow M. Randomised trial of dobutamine versus dopamine in preterm infants with low systemic blood flow J Pediatr 2002 ;
140: 183-190.
584. Osborn DA, Paradisis M, Evans N. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow.
Cochrane Datebase of Systematic Reviews 2007; Issue 1.[DOI:10.1002/14651858. CD005090]
585. Berrington KJ, Finer NN, Chan WKY. A blind randomized comparison of the circulatory effects of dopamine and epinrphline infusion in the newborn
piglet during normoxia and hypoxia.Critical Care Medicine 1995; 23: 740-748.
586. Paradisis M, Osborn DA. Adrenalin for prevention of morvidity and mortality in preterm infants with cardiovascular compromise. Cochrane Datebase of
Systematic Reviews 2004; Issue 1.[DOI:10.1002/14651858.CD003958]
587. 2005 International Liaison Committee on Resuscitation, American Heart Association, and European Resuscitation Counci. 2005 American Heart
Association Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Part7. Neonatal Resuscitaion. Circulation 2005;
112(suppl): Ⅲ 91-99.
588. 日本版救急蘇生ガイドライン2010に基づく新生児蘇生法テキスト 改訂第2版．東京，メディカルビュー社 2010: 76-83.
589. Ng PC, Lam CW, Fok TF, et al. Refractory hypotention in preterm infants with adrenocorticol insufficiency.Arch Dis Childlh: Fetal and Neonatal Edn
2001; 84: F122-124.
590. Seri I. Hydrocortisone and vasopuressor-resistant shock in preterm neonates Pediatr 2006; 117: 516-518.
591. Ng PC, Cheuk LH, Bnur FL, et al . A double blind,randomized,controlled study of a stress dose of hydrocortisone for rescue treatment of refractory
hypotention in preterm infants. Pediatr 2006; 117: 367-375.
592. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91:
283-290.
593. Van Marter LJ. Persistent pulmonary hypertension of the newborn. Manual of neonatal care 6th edn. Philadelphia, PA: Lippincott 2008: 358-364.
594. Kinsella JP, Abman SH. Clinical approach to inhaled NO therapy in the newborn. J pediatrics 2000; 136: 717-726.
595. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistant pulmonary hypertention of the newborn. N Engl J Med 2000;
342: 469-474.
596. Finer N, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term(Review). Cochrane Database Syst Rev 2006; 4: CD000399.
597. Rang HP, Dale MM, Ritter JM, et al. Rang and Dole’spharmacology, 6th edn. Philadelphia, PA: Churchill Livingstone Elsevier 2007: 331-346.
598. 佐地勉，山田修，中山智孝，他．小児期肺動脈性肺高血圧症症例におけるエポプロステノール治療の有効性と安全性の長期検討―市販後使用成績調査から
の検討―．心臓2008; 40: 34-43.
599. Bronen M. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997; 18: 3-7.
600. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study.
Pediatrics 2006; 117: 1077-1083.
小児期心疾患における薬物療法ガイドライン
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）